OKYO Pharma CEO to Present at Boston Drug Discovery Summit

OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has shared an update.

On May 19, 2025, OKYO Pharma announced that its CEO, Dr. Gary S. Jacob, will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will focus on urcosimod, OKYO’s lead clinical drug candidate, which is being developed to treat neuropathic corneal pain, a severe condition affecting many worldwide. This event highlights OKYO’s ongoing efforts to advance its drug development pipeline and strengthen its position in the biopharmaceutical industry, potentially impacting stakeholders by showcasing the company’s innovative approach to treating ocular diseases.

The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is dedicated to discovering and developing novel molecules to address these ocular conditions, with its ordinary shares listed on the NASDAQ Capital Market.

Average Trading Volume: 112,546

Technical Sentiment Signal: Buy

Current Market Cap: $50.15M

For an in-depth examination of OKYO stock, go to TipRanks’ Stock Analysis page.